Steven O’Day

47.2k total citations · 5 hit papers
198 papers, 12.9k citations indexed

About

Steven O’Day is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Steven O’Day has authored 198 papers receiving a total of 12.9k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Oncology, 88 papers in Molecular Biology and 79 papers in Immunology. Recurrent topics in Steven O’Day's work include Cancer Immunotherapy and Biomarkers (72 papers), Immunotherapy and Immune Responses (64 papers) and CAR-T cell therapy research (63 papers). Steven O’Day is often cited by papers focused on Cancer Immunotherapy and Biomarkers (72 papers), Immunotherapy and Immune Responses (64 papers) and CAR-T cell therapy research (63 papers). Steven O’Day collaborates with scholars based in United States, France and Germany. Steven O’Day's co-authors include Omid Hamid, Jeffrey S. Weber, Jedd D. Wolchok, Axel Hoos, Célèste Lebbé, F. Stephen Hodi, Michele Maio, Rachel Humphrey, Geoffrey Nichol and Michael Binder and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Steven O’Day

195 papers receiving 12.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

2009 2.3k citations Jedd D. Wolchok, Steven O’Day et al. Clinical Cancer Research profile →
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

2009 934 citations Jedd D. Wolchok, Bart Neyns et al. profile →
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

2012 719 citations Gerald S. Falchook, Georgina V. Long et al. profile →
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

2013 350 citations Steven O’Day, Gary K. Schwartz et al. Journal of Clinical Oncology profile →
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

2013 233 citations Jedd D. Wolchok, F. Stephen Hodi et al. profile →

Peers

Countries citing papers authored by Steven O’Day

Since Specialization

Citations

This map shows the geographic impact of Steven O’Day's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven O’Day with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven O’Day more than expected).

Fields of papers citing papers by Steven O’Day

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven O’Day. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven O’Day. The network helps show where Steven O’Day may publish in the future.

Co-authorship network of co-authors of Steven O’Day

This figure shows the co-authorship network connecting the top 25 collaborators of Steven O’Day. A scholar is included among the top collaborators of Steven O’Day based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven O’Day. Steven O’Day is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas 2025 ·Journal of Clinical Oncology ·Breelyn A. Wilky, Gary K. Schwartz, Michael S. Gordon, Anthony B. El-Khoueiry, Andrea J. Bullock, Brian S. Henick, Mark Agulnik, Arun S. Singh, Daruka Mahadevan, Justin Stebbing, Chloé Delépine, Dhan Chand, (unknown), (unknown), Benny Johnson, Joseph E. Grossman, Steven O’Day, Jonathan C. Trent, Robin L. Jones, Apostolia M. Tsimberidou	9
2	Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study 2023 ·Cancer Research Communications ·Pamela N. Münster, Nicholas Iannotti, Daniel C. Cho, John M. Kirkwood, Liza C. Villaruz, Geoffrey T. Gibney, F. Stephen Hodi, Niharika B. Mettu, Mark Jones, (unknown), Michael Smith, Mani Lakshminarayanan, Steven O’Day	5
3	Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules 2021 ·Clinical Cancer Research ·Georgina V. Long, Caroline Robert, Marcus O. Butler, Félix Couture, Matteo S. Carlino, Steven O’Day, Victoria Atkinson, Jonathan Cebon, Michael P. Brown, Stéphane Dalle, Andrew Hill, Geoffrey T. Gibney, Steven McCune, Alexander M. Menzies, (unknown), Nageatte Ibrahim, Blanca Homet Moreno, Adi Diab	24
4	The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response 2020 ·Journal for ImmunoTherapy of Cancer ·Fernanda I. Arnaldez, Steven O’Day, Charles G. Drake, Bernard A. Fox, (unknown), Walter J. Urba, Vincenzo Montesarchio, Jeffrey S. Weber, Haiming Wei, Jon M. Wigginton, Paolo A. Ascierto	68
5	A Pilot Study Comparing the Efficacy of Lactate Dehydrogenase Levels Versus Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients 2020 ·Cancers ·Matías A. Bustos, (unknown), Negin Rahimzadeh, (unknown), (unknown), Kevin Tran, (unknown), Stacey L. Stern, Steven O’Day, Dave S.�B. Hoon	30
6	Integrated Assessment of Circulating Cell-Free MicroRNA Signatures in Plasma of Patients with Melanoma Brain Metastasis 2020 ·Cancers ·Matías A. Bustos, Kevin Tran, Negin Rahimzadeh, (unknown), Selena Y. Lin, Yoshiaki Shoji, Tomohiro Murakami, (unknown), (unknown), (unknown), Daniel F. Kelly, Steven O’Day, Dave S.�B. Hoon	24
7	LBA44 Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004 2020 ·Annals of Oncology ·Ana Arance, Steven O’Day, Luis de la Cruz‐Merino, Teresa M. Petrella, (unknown), Lars Ny, Ana Carneiro, Alfonso Berrocal, Iván Márquez‐Rodas, Anna Spreafico, Victoria Atkinson, Fernanda Costa Svedman, A. David Smith, (unknown), Scott J. Diede, Clemens Krepler, Georgina V. Long	19
8	Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients 2018 ·Annals of Oncology ·Charles M. Rudin, Hardev Pandha, Sumati Gupta, Matthew R. Zibelman, Wallace Akerley, Daphne Day, Andrew Hill, Rachel E. Sanborn, Steven O’Day, Timothy Clay, Gavin Wright, Ross Jennens, David E. Gerber, Jonathan E. Rosenberg, Christy Ralph, David C. Campbell, Brendan D. Curti, Emmett V. Schmidt, Mark Grose, Darren R. Shafren	15
9	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition 2015 ·Clinical Cancer Research ·Richard D. Carvajal, Donald P. Lawrence, Jeffrey S. Weber, Thomas F. Gajewski, René González, Jose Lutzky, Steven O’Day, Omid Hamid, Jedd D. Wolchok, Paul B. Chapman, Ryan J. Sullivan, Jerrold B. Teitcher, Nikhil H. Ramaiya, Anita Giobbie‐Hurder, Cristina R. Antonescu, Michael C. Heinrich, Boris C. Bastian, Christopher L. Corless, Jonathan A. Fletcher, F. Stephen Hodi	97
10	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436) 2014 ·Clinical Cancer Research ·Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, (unknown), (unknown), Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna C. Pavlick, Melvin Chin, Steven O’Day, Samuel C. Blackman, C. Martin Curtis, Peter F. Lebowitz, Bo Ma, Danièle Ouellet, Richard Kefford	51
11	Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies 2014 ·Annals of Oncology ·Célèste Lebbé, Jeffrey S. Weber, Michele Maio, Bart Neyns, Kaan Harmankaya, Omid Hamid, Steven O’Day, Cyril Konto, (unknown), M. Brent McHenry, Jedd D. Wolchok	118
12	Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) 2013 ·Clinical Cancer Research ·Katherine L. Nathanson, Anne‐Marie Martin, Bradley Wubbenhorst, Joel Greshock, Richard Letrero, Kurt D’Andrea, Steven O’Day, Jeffrey R. Infante, Gerald S. Falchook, Hendrik‐Tobias Arkenau, Michael Millward, Michael P. Brown, Anna C. Pavlick, Michael A. Davies, Bo Ma, Robert Gagnon, (unknown), Peter F. Lebowitz, Richard Kefford, Georgina V. Long	132
13	Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. 2013 ·PubMed Central ·Jeffrey S. Weber, Omid Hamid, Asim Amin, Steven O’Day, Eric Masson, S. Goldberg, (unknown), Susan Parker, Scott D. Chasalow, Suresh Alaparthy, Jedd D. Wolchok	58
14	Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20) 2013 ·Annals of Oncology ·David F. McDermott, John B.A.G. Haanen, Tai‐Tsang Chen, Paul Lorigan, Steven O’Day	168
15	BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma 2011 ·Journal of Clinical Oncology ·Kevin B. Kim, Jeffrey A. Sosman, John P. Fruehauf, Gerald P. Linette, Svetomir N. Markovic, David F. McDermott, Jeffrey S. Weber, Hoa Nguyen, Peter Cheverton, Daniel S. Chen, Amy Peterson, William E. Carson, Steven O’Day	148
16	A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin α_vβ₃, ± dacarbazine in patients with stage IV metastatic melanoma 2010 ·Cancer ·Peter Hersey, Jeffrey A. Sosman, Steven O’Day, Jon Richards, Agop Y. Bedikian, René González, William H. Sharfman, Robert Weber, Theodore F. Logan, Manuela Buzoianu, Luz Hammershaimb, John M. Kirkwood	150
17	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma 2009 ·Clinical Cancer Research ·Jeffrey S. Weber, John A. Thompson, Omid Hamid, David R. Minor, Asim Amin, Ilan G. Ron, Ruggero Ridolfi, Hazem Assi, Anthony Maraveyas, David M. Berman, Jonathan Siegel, Steven O’Day	460
18	Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) 2007 ·Cancer ·Steven O’Day, Omid Hamid, Walter J. Urba	245
19	Enhanced Survival Associated with Vitiligo Expression during Maintenance Biotherapy for Metastatic Melanoma 2006 ·Journal of Investigative Dermatology ·Peter D. Boasberg, Dave S.�B. Hoon, Lawrence D. Piro, Maureen Martin, (unknown), (unknown), (unknown), Xing Ye, (unknown), Steven O’Day	79
20	Biochemotherapy for Metastatic Melanoma with Limited Central Nervous System Involvement 2003 ·Oncology ·Peter D. Boasberg, Steven O’Day, (unknown), Maureen Martin, Hong Wang, (unknown), (unknown), (unknown), (unknown), Zbigniew Petrovich	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact